Profile data is unavailable for this security.
About the company
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.
- Revenue in USD (TTM)0.00
- Net income in USD-6.93m
- Incorporated2009
- Employees16.00
- LocationEdesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
- Phone+1 (905) 475-1234
- Fax+1 (905) 475-1234
- Websitehttps://www.edesabiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burzynski Research Institute Inc | 0.00 | -1.54m | 6.44m | 2.00 | -- | -- | -- | -- | -0.0117 | -0.0117 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -89,888.89 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.06m | 6.44m | 3.00 | -- | 1.30 | -- | -- | -80.15 | -80.15 | 0.00 | 0.1002 | 0.00 | -- | -- | 0.00 | -350.34 | -132.47 | -2,116.75 | -185.75 | -- | -- | -- | -- | -- | -- | 0.0092 | -- | -- | -- | -23.42 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -13.03m | 6.53m | 4.00 | -- | 1.11 | -- | -- | -4.49 | -4.50 | 0.00 | 0.9185 | 0.00 | -- | -- | 0.00 | -272.04 | -182.35 | -316.95 | -235.45 | -- | -- | -- | -- | -- | -16.22 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -14.93m | 6.56m | 10.00 | -- | 3.97 | -- | -- | -8.49 | -8.49 | 0.00 | 0.0957 | 0.00 | -- | -- | 0.00 | -210.77 | -133.14 | -475.23 | -181.26 | -- | -- | -- | -- | -- | -40.02 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -14.23m | 6.59m | 29.00 | -- | -- | -- | -- | -3.46 | -3.46 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -369.22 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -35.87 | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NLS Pharmaceutics AG | 0.00 | -6.60m | 6.66m | 3.00 | -- | -- | -- | -- | -6.72 | -6.72 | 0.00 | -9.40 | 0.00 | -- | -- | 0.00 | -380.82 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -27.20 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 6.79m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 6.85m | 16.00 | -- | 2.39 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 354.91k | -545.87k | 6.86m | 2.00 | -- | -- | -- | 19.33 | -0.00005 | -0.00005 | 0.00003 | -0.0001 | 8.98 | -- | 15.71 | 177,455.00 | -1,381.60 | -- | -- | -- | 87.28 | -- | -153.81 | -- | -- | -2.16 | -- | -- | -21.46 | -- | 36.92 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -13.24m | 6.91m | 7.00 | -- | -- | -- | -- | -8.82 | -8.82 | 0.00 | -0.4198 | 0.00 | -- | -- | 0.00 | -198.45 | -87.52 | -594.46 | -116.56 | -- | -- | -- | -- | -- | -128.86 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 6.98m | 68.00 | -- | -- | -- | 18.07 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Biora Therapeutics Inc | 892.00k | -35.57m | 7.07m | 58.00 | -- | -- | -- | 7.93 | -12.92 | -11.78 | 0.2163 | -28.99 | 0.0363 | -- | 1.06 | 15,379.31 | -144.59 | -122.84 | -- | -369.01 | -- | -- | -3,988.12 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Plus Therapeutics Inc (USA) | 5.73m | -12.89m | 7.08m | 20.00 | -- | -- | -- | 1.24 | -2.42 | -2.42 | 0.988 | -0.8775 | 0.5653 | -- | -- | 286,250.00 | -127.22 | -59.18 | -- | -133.04 | -- | -- | -225.07 | -470.45 | -- | -4.31 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| ABVC Biopharma Inc | 509.80k | -8.24m | 7.14m | 16.00 | -- | 0.8363 | -- | 14.00 | -0.9744 | -0.9744 | 0.0508 | 0.6576 | 0.0328 | -- | 1.60 | 31,862.50 | -56.14 | -103.38 | -88.09 | -231.54 | 72.54 | 76.25 | -1,710.03 | -2,019.89 | -- | -2.62 | 0.1856 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.19m | -10.42m | 7.19m | 13.00 | -- | 1.18 | -- | 2.26 | -27.94 | -27.94 | 1.42 | 1.39 | 0.3121 | 1.93 | 5.56 | 245,228.50 | -102.35 | -71.59 | -255.70 | -144.36 | 48.31 | -- | -327.90 | -565.48 | 1.01 | -- | 0.0775 | -- | 147.58 | 596.39 | 4.47 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Edesa Biotech Inc's reporting currency: US Dollar USD
4.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CM Management LLCas of 30 Sep 2024 | 110.00k | 3.39% |
| Geode Capital Management LLCas of 30 Sep 2024 | 20.81k | 0.64% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 15.70k | 0.48% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 11.33k | 0.35% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2024 | 1.74k | 0.05% |
| Tower Research Capital LLCas of 30 Sep 2024 | 1.02k | 0.03% |
| Avion Wealth LLCas of 30 Sep 2024 | 242.00 | 0.01% |
| Vanguard Global Advisers LLCas of 30 Sep 2024 | 162.00 | 0.01% |
| TD Waterhouse Canada, Inc.as of 30 Sep 2024 | 142.00 | 0.00% |
| Fifth Third Bank, NA (Investment Management)as of 30 Sep 2024 | 100.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
